TURBO OPTIONSSCHEIN - VIVORYON THERAPEUTICS | Market Closed - Börse Stuttgart 02:11:01 2024-06-28 am EDT | ||
| 1.73 EUR | +32.06% |
|
| Current month | +6.13% | ||
| 1 month | -62.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 1.73 | +32.06% |
| 24-06-27 | 1.31 | -9.66% |
| 24-06-26 | 1.45 | -14.20% |
| 24-06-25 | 1.69 | -2.31% |
| 24-06-24 | 1.73 | -4.42% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:11 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX34JU |
| ISIN | DE000LX34JU2 |
| Date issued | 2024-04-24 |
| Strike | 0.6 € |
| Maturity | 2024-12-12 (166 Days) |
| Parity | 1 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 0.07 € |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2023, the group has a portfolio of a product in phase II-B clinical development (Varoglutamstat; PQ912).
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.85
EUR
Average target price
41.57
EUR
Spread / Average Target
+2,146.85%
- Stock Market
- Certificates
- Certificat
